GLP-1 Agonists for Weight Loss: Ozempic, Wegovy, and Mounjaro Explained

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 agonists like Ozempic, Wegovy, and Mounjaro promote weight loss by reducing appetite and improving metabolism, offering effective treatment options for obesity.

# GLP-1 Agonists for Weight Loss: Ozempic, Wegovy, and Mounjaro

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a powerful class of medications primarily used to treat type 2 diabetes. However, their significant effects on appetite suppression and weight loss have positioned them as important tools in obesity management. Among these, Ozempic, Wegovy, and Mounjaro are three prominent GLP-1 receptor agonists gaining widespread attention for weight loss. This article reviews their mechanisms of action, dosing protocols, efficacy, and safety profiles to help individuals understand how these drugs work and who might benefit from them.

---

What Are GLP-1 Receptor Agonists?

GLP-1 is a hormone secreted by the intestines in response to food intake. It helps regulate blood glucose by promoting insulin secretion, slowing gastric emptying, and reducing appetite through effects on the central nervous system.

GLP-1 receptor agonists are synthetic analogs that mimic the action of GLP-1 but have longer half-lives, making them effective drugs for:

  • Improving blood sugar control in type 2 diabetes
  • Promoting weight loss by decreasing hunger and caloric intake

    • The three drugs—Ozempic, Wegovy, and Mounjaro—are injectable, once-weekly medications that vary in their approved indications, dosing, and weight-loss outcomes.

    ---

    Ozempic (Semaglutide)

    Overview and Indications

  • Generic name: Semaglutide
  • Indication: Approved for type 2 diabetes management; frequently prescribed off-label for weight loss.
  • Administration: Subcutaneous injection, once weekly.

    • Mechanism of Action

    Ozempic activates GLP-1 receptors, enhancing insulin secretion when glucose is elevated, reducing glucagon secretion, delaying gastric emptying, and promoting satiety.

    Dosing Protocol for Weight Loss (Off-label)

    Although Ozempic is FDA-approved for type 2 diabetes (starting dose 0.25 mg weekly titrating to 1 mg weekly), for weight loss:

  • Starting at 0.25 mg/week for 4 weeks (to minimize gastrointestinal side effects)
  • Increase to 0.5 mg/week for at least 4 weeks
  • Some clinicians may titrate up to 1 mg/week based on tolerance

    • Evidence on Weight Loss

  • Clinical trials show patients with type 2 diabetes using Ozempic can lose an average of 5-10% of body weight.
  • Weight loss is often less than with high-dose semaglutide formulations designed specifically for obesity.

    • ---

    Wegovy (Semaglutide)

    Overview and Indications

  • Generic name: Semaglutide
  • Indication: FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with related comorbidities.
  • Administration: Subcutaneous injection, once weekly.

    • Mechanism of Action

    Similar to Ozempic, but used at higher doses to specifically target weight loss.

    Dosing Protocol

    The FDA-approved dose for weight loss with Wegovy is higher than that for Ozempic:

  • Initiate at 0.25 mg once weekly for 4 weeks
  • Increase every 4 weeks following this schedule:

    • - 0.5 mg for 4 weeks

    - 1 mg for 4 weeks

    - 1.7 mg for 4 weeks

    - 2.4 mg maintenance dose weekly thereafter

    Dose escalation helps reduce gastrointestinal adverse effects.

    Evidence on Weight Loss

  • STEP clinical trials demonstrated an average 15% weight loss after 68 weeks at the 2.4 mg weekly dose.
  • This represents a substantial improvement over older weight-loss medications.
  • Wegovy is associated with better improvements in metabolic parameters and risk factors related to obesity.

    • ---

    Mounjaro (Tirzepatide)

    Overview and Indications

  • Generic name: Tirzepatide
  • Indication: FDA-approved for type 2 diabetes management and recently investigated for weight loss.
  • Administration: Subcutaneous injection, once weekly.

    • Mechanism of Action

    Mounjaro is a dual agonist for:

  • GLP-1 receptors (like Ozempic and Wegovy)
  • Glucose-dependent insulinotropic polypeptide (GIP) receptors

    • This dual action may enhance insulin secretion and reduce appetite more potently.

    Dosing Protocol for Weight Loss

  • Usually prescribed starting at 2.5 mg/week for 4 weeks
  • Titrated every 4 weeks up to a target dose (typically 7.5 mg to 15 mg weekly, depending on tolerance and patient response)

    • Evidence on Weight Loss

  • SURMOUNT-1 trial showed that tirzepatide 15 mg weekly led to mean weight loss of up to 20.9% after 72 weeks in people with obesity, even without diabetes.
  • This is currently the highest weight loss reported among GLP-1 agonists and dual agonists.

    • ---

    Safety and Side Effects

    All GLP-1 receptor agonists share similar side effects, primarily related to their gastrointestinal effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain

    • These side effects generally improve with gradual dose escalation.

    Rare but serious risks include:

  • Pancreatitis
  • Gallbladder disease
  • Possible thyroid C-cell tumors (seen in animal studies)

    • Contraindications:

  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • History of pancreatitis (caution advised)

    • ---

    Practical Protocol Considerations

  • Patient Selection: Best candidates are adults with BMI ≥30 or ≥27 with weight-related comorbidities (e.g., hypertension, type 2 diabetes).
  • Monitoring: Regular follow-up every 4-6 weeks during dose escalation to monitor side effects and efficacy.
  • Lifestyle: Medications should be combined with lifestyle interventions including diet and exercise.
  • Provider Consultation: Patients should always consult their healthcare provider to assess suitability, dosing, and to monitor for adverse effects.

    • ---

    Conclusion

    GLP-1 receptor agonists have revolutionized pharmacologic options for weight loss. Ozempic and Mounjaro, while approved primarily for diabetes, have potent weight loss effects, with Ozempic commonly used off-label. Wegovy is the first semaglutide formulation specifically FDA-approved for obesity treatment, delivering significant weight reduction. Mounjaro’s dual GLP-1/GIP receptor activity shows even greater promise for substantial and sustained weight loss.

    For individuals struggling with obesity or overweight with comorbidities, these medications offer clinically meaningful weight loss when used alongside lifestyle changes. However, proper medical supervision is essential to optimize dosing, minimize side effects, and ensure safety.

    ---

    References

  • Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002.
  • Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515.
  • Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA. 2021;325(14):1414-1425.
  • Centers for Disease Control and Prevention. "Preventing Obesity." https://www.cdc.gov/obesity/strategies/index.html

    • ---

    Note: This article is for informational purposes only and does not substitute professional medical advice. Consult your healthcare provider before starting any medication or weight management program.